Skip to content
HowShorted

Dianthus Therapeutics, Inc. short interest in 2022

In 2022, Dianthus Therapeutics, Inc.'s disclosed short interest ran from 1.70% of shares outstanding on 14 Jan 2022 to 0.49% on 30 Nov 2022, a change of -1.21 percentage points. The year's high was 2.98% on 15 Jun 2022 and its low 0.49% on 30 Nov 2022, averaging 1.45% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.93 days on 15 Jun 2022. Full history: Dianthus Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Dianthus Therapeutics, Inc. in 2022

2022 in figures

Start of year
1.70% (14 Jan 2022)
End of year
0.49% (30 Nov 2022)
Change
-1.21 pp
High
2.98% (15 Jun 2022)
Low
0.49% (30 Nov 2022)
Average
1.45%
Highest days to cover
9.93 (15 Jun 2022)
SEC filings marked
9

Every report in 2022

Dianthus Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20221.70%3.08results (8-K)
31 Jan 20221.28%1.00
15 Feb 20221.66%4.50
28 Feb 20222.21%4.69
15 Mar 20222.25%5.8110-K filed, results (8-K)
31 Mar 20221.67%4.18
14 Apr 20221.64%7.64
29 Apr 20222.49%6.10
13 May 20222.41%3.42
31 May 20222.80%3.8810-Q filed, results (8-K)
15 Jun 20222.98%9.93
30 Jun 20221.47%1.55
15 Jul 20220.99%2.01
29 Jul 20220.88%7.30
15 Aug 20220.82%4.9710-Q filed, results (8-K)
31 Aug 20220.70%1.71
15 Sep 20220.78%1.81
30 Sep 20220.81%3.56
14 Oct 20220.71%4.02
31 Oct 20220.67%4.56
15 Nov 20220.53%2.0110-Q filed, results (8-K)
30 Nov 20220.49%1.85

See also: Dianthus Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.